Diagnostic Center | June 05, 2025
Allarity announces enrolment of first patient in phase 2 clinical trial protocol of Stenoparib in advanced ovarian cancer
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
